Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Bone metastases are major sequelae of non-small-cell lung cancer and are associated with poor survival, skeletal-related events (SREs), and economic burden. In recent phase III trials, zoledronic acid has demonstrated a potential to prevent or delay SREs, although this has not yet translated into a survival benefit. Zoledronic acid is the first and only bisphosphonate with proven efficacy in the treatment of bone metastases associated with a broad range of tumors, including lung cancer. We report herein a case study that highlights the clinical benefit of zoledronic acid in a patient with squamous cell carcinoma of the lung.
Langer
Corey J
CJ
Fox Chase Cancer Center, Philadelphia, PA 19111, USA. cj_langer@fccc.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010005:Osteoarthropathy, Secondary Hypertrophic / Q000209:etiology; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid